Portland, OR, July 04, 2022 (GLOBE NEWSWIRE) — As per the report published by Allied Market Research, the global Preimplantation Genetics Diagnosis (PGD) Market was accounted for $81.52 billion in 2020, and is estimated to reach $217.19 billion by 2030, growing at a CAGR of 10.4% from 2021 to 2030.
Increase in consumption of alcohol, drug, poor diet, and smoking, surge in stress among people, and rise in health problems associated with hormones have boosted the growth of the global preimplantation genetics diagnosis (PGD) market. However, high costs involved for various diagnosis hamper the market growth. On the contrary, increase in number of patients suffering from genetic disorders and surge in hereditary diseases are expected to open new opportunities in the future.
Download Sample PDF at: https://www.alliedmarketresearch.com/request-sample/1470
Covid-19 scenario:
- The Covid-19 pandemic significantly increased the importance of government healthcare facilities and healthcare expenditure across the globe.
- However, as the number of Covid-19 patients have reduced, the companies that offer PGD reopened and established new methods of working post-pandemic.
The report divides the global preimplantation genetics diagnosis (PGD) market on the basis of type and region.
Based on type, the aneuploidy segment held the largest share in 2020, accounting for nearly one-fourth of the market. However, the chromosomal abnormalities segment is projected to manifest the highest…
